CytoSorbents Corp. (CTSO) Stock Recommendation | Score, Valuation, Technicals & Financial Trend

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.Unlock 29 Markets

Comparison

Company

Score

Quality

Valuation

Financial

Technical

Electromed, Inc.

Apyx Medical Corp.

KORU Medical Systems, Inc.

Hyperfine, Inc.

Clearpoint Neuro, Inc.

DarioHealth Corp.

CytoSorbents Corp.

Accelerate Diagnostics, Inc.

Cutera, Inc.

Vicarious Surgical, Inc.

Citius Pharmaceuticals, Inc.

Why is CytoSorbents Corp. ?

With a Operating Losses, the company has a Weak Long Term Fundamental Strength

Poor long term growth as Operating profit has grown by an annual rate -1.99% of over the last 5 years
Company's ability to service its debt is weak with a poor EBIT to Interest (avg) ratio of -21.28

Flat results in Jun 25

INTEREST(HY) At USD 1.22 MM has Grown at 553.88%
DEBTORS TURNOVER RATIO(HY) Lowest at 4.4 times

Risky - Negative EBITDA

The stock is trading risky as compared to its average historical valuations
Over the past year, while the stock has generated a return of -10.02%, its profits have risen by 42.8%

Consistent Underperformance against the benchmark over the last 3 years

Along with generating -10.02% returns in the last 1 year, the stock has also underperformed S&P 500 in each of the last 3 annual periods

Real-Time Research Report

Verdict Report

How much should you sell?

All quantity irrespective of whether you are making profits or losses

(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)

When to re-enter? - We will constantly monitor the company and review our call based on new data

Is CytoSorbents Corp. for you?

High Risk, Low Return

Absolute

Risk Adjusted

Volatility

CytoSorbents Corp.

-22.21%

-0.07

80.14%

S&P 500

13.22%

0.61

20.17%

Quality

Management Risk

Growth

Capital Structure

Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors

Factor

Value

Sales Growth (5y)

1.36%

EBIT Growth (5y)

-1.99%

EBIT to Interest (avg)

-21.28

Debt to EBITDA (avg)

Negative Net Debt

Net Debt to Equity (avg)

0.23

Sales to Capital Employed (avg)

1.31

Tax Ratio

9.65%

Dividend Payout Ratio

Pledged Shares

Institutional Holding

32.69%

ROCE (avg)

ROE (avg)

Valuation

Valuation Scorecard

Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors

Factor

Value

P/E Ratio

NA (Loss Making)

Industry P/E

Price to Book Value

4.56

EV to EBIT

-3.86

EV to EBITDA

-4.26

EV to Capital Employed

3.90

EV to Sales

2.02

PEG Ratio

Dividend Yield

ROCE (Latest)

-101.11%

ROE (Latest)

-107.06%

Technicals

Technical key factors

Indicator

Weekly

Monthly

MACD

Bearish

Mildly Bullish

RSI

No Signal

Bollinger Bands

Mildly Bearish

Moving Averages

Mildly Bearish (Daily)

KST

Bearish

Mildly Bullish

Dow Theory

Mildly Bearish

OBV

Mildly Bearish

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Technical Movement

Analyse All Technical Factors

Financial Trend

Financial Trend Scorecard

Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

20What is working for the Company

OPERATING CASH FLOW(Y)

Highest at USD -9.77 MM

ROCE(HY)

Highest at -68.84%

PRE-TAX PROFIT(Q)

Highest at USD 1.95 MM

NET PROFIT(Q)

Highest at USD 1.95 MM

EPS(Q)

Highest at USD 0.03

-9What is not working for the Company

INTEREST(HY)

At USD 1.22 MM has Grown at 553.88%

DEBTORS TURNOVER RATIO(HY)

Lowest at 4.4 times

Here's what is working for CytoSorbents Corp.

Operating Cash Flow

Highest at USD -9.77 MM and Grown

In each year in the last three years

MOJO Watch

The company has generated higher cash revenues from business operations

Operating Cash Flows (USD MM)

Pre-Tax Profit

At USD 1.95 MM has Grown at 145.12%

over average net sales of the previous four periods of USD -4.32 MM

MOJO Watch

Near term Pre-Tax Profit trend is very positive

Pre-Tax Profit (USD MM)

Net Profit

At USD 1.95 MM has Grown at 150.02%

over average net sales of the previous four periods of USD -3.89 MM

MOJO Watch

Near term Net Profit trend is very positive

Net Profit (USD MM)

Pre-Tax Profit

Highest at USD 1.95 MM

in the last five periods

MOJO Watch

Near term Pre-Tax Profit trend is positive

Pre-Tax Profit (USD MM)

Net Profit

Highest at USD 1.95 MM

in the last five periods

MOJO Watch

Near term Net Profit trend is positive

Net Profit (USD MM)

EPS

Highest at USD 0.03

in the last five periods

MOJO Watch

Increasing profitability; company has created higher earnings for shareholders

EPS (USD)

Here's what is not working for CytoSorbents Corp.

Interest

At USD 1.22 MM has Grown at 553.88%

over previous Semi-Annual period

MOJO Watch

Rising interest cost signifies increased borrowings

Interest Paid (USD MM)

Debtors Turnover Ratio

Lowest at 4.4 times

in the last five Semi-Annual periods

MOJO Watch

Company's pace of selling Debtors has slowed

Debtors Turnover Ratio